These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

147 related items for PubMed ID: 38316401

  • 21. Role of octreotide, scopolamine butylbromide, and hydration in symptom control of patients with inoperable bowel obstruction and nasogastric tubes: a prospective randomized trial.
    Ripamonti C, Mercadante S, Groff L, Zecca E, De Conno F, Casuccio A.
    J Pain Symptom Manage; 2000 Jan; 19(1):23-34. PubMed ID: 10687323
    [Abstract] [Full Text] [Related]

  • 22. Multicenter prospective study on efficacy and safety of octreotide for inoperable malignant bowel obstruction.
    Hisanaga T, Shinjo T, Morita T, Nakajima N, Ikenaga M, Tanimizu M, Kizawa Y, Maeno T, Shima Y, Hyodo I.
    Jpn J Clin Oncol; 2010 Aug; 40(8):739-45. PubMed ID: 20410056
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Octreotide improved the quality of life in a child with malignant bowel obstruction caused by peritoneal dissemination of colon cancer.
    Watanabe H, Inoue Y, Uchida K, Okugawa Y, Hiro J, Ojima E, Kobayashi M, Miki C, Kusunoki M.
    J Pediatr Surg; 2007 Jan; 42(1):259-60. PubMed ID: 17208578
    [Abstract] [Full Text] [Related]

  • 26. Bowel obstruction in home-care cancer patients: 4 years experience.
    Mercadante S.
    Support Care Cancer; 1995 May; 3(3):190-3. PubMed ID: 7544674
    [Abstract] [Full Text] [Related]

  • 27. Double-blind, placebo-controlled, randomized trial of octreotide in malignant bowel obstruction.
    Currow DC, Quinn S, Agar M, Fazekas B, Hardy J, McCaffrey N, Eckermann S, Abernethy AP, Clark K.
    J Pain Symptom Manage; 2015 May; 49(5):814-21. PubMed ID: 25462210
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Malignant irreversible intestinal obstruction: the powerful association of octreotide to corticosteroids, antiemetics, and analgesics.
    Weber C, Zulian GB.
    Am J Hosp Palliat Care; 2009 May; 26(2):84-8. PubMed ID: 19088264
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Management of malignant bowel obstruction.
    Ripamonti CI, Easson AM, Gerdes H.
    Eur J Cancer; 2008 May; 44(8):1105-15. PubMed ID: 18359221
    [Abstract] [Full Text] [Related]

  • 34. Octreotide in relieving gastrointestinal symptoms due to bowel obstruction.
    Mercadante S, Spoldi E, Caraceni A, Maddaloni S, Simonetti MT.
    Palliat Med; 1993 May; 7(4):295-9. PubMed ID: 7505187
    [Abstract] [Full Text] [Related]

  • 35. [Clinical efficacy of octreotide acetate in cancer patients with malignant bowel symptoms depend on terminal stage].
    Uchino R, Kusano S, Hanada N, Ohara C, Okino T, Yamaguchi K.
    Gan To Kagaku Ryoho; 2011 Feb; 38(2):255-7. PubMed ID: 21368489
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.